Executive Search Success Story: Building the Technical Leadership Team to Modernize Aseptic Operations and Achieve Annex 1 Compliance at a Generic Injectables Manufacturer

How JRG Partners executed a confidential, multi-role North American executive search strategy that equipped a generic sterile injectables manufacturer with the operations, sterility assurance, engineering, regulatory CMC, and manufacturing science leadership required to convert legacy open-cleanroom filling to isolator and barrier technology, meet revised EU Annex 1 requirements, and protect European and U.S. supply across 90 products.

The Challenge

A generic sterile injectables manufacturer operated legacy open-cleanroom filling lines across three facilities, and European regulators had signaled that its contamination control strategy would not meet revised Annex 1 expectations at the next inspection. Converting to isolator and restricted access barrier technology meant redesigning lines while maintaining supply of 90 products, revalidating aseptic processes, filing hundreds of regulatory variations across U.S. and European authorities, and retraining the workforce, all without the sterility assurance, barrier engineering, or CMC regulatory depth the program demanded. Executive leadership identified several critical vulnerabilities threatening the company:

• Legacy open-cleanroom filling unlikely to meet revised Annex 1 expectations at the next European inspection
• Contamination control strategy and environmental monitoring below current regulatory expectations
• No internal isolator or barrier technology engineering experience
• Hundreds of regulatory variations required across 90 products in multiple jurisdictions
• Aseptic process revalidation and media fills across three facilities while maintaining supply
• Risk of European market loss and U.S. shortages if the program slipped

Recognizing that the program required technical leadership the company did not have, the Chief Executive Officer and Chief Quality Officer engaged JRG Partners to recruit a Vice President of Sterile Operations, Vice President of Sterility Assurance & Microbiology, Vice President of Engineering & Barrier Technology, Vice President of Regulatory Affairs for CMC, and Vice President of Manufacturing Science & Technology. The company required an executive search partner with deep sterile fill-finish expertise and access to leaders who had led Annex 1 and isolator conversions.

Why They Chose JRG Partners

Sterile Fill-Finish Practice Focus

JRG Partners maintains a dedicated practice recruiting sterile fill-finish leadership, with a clear understanding of Annex 1 requirements, contamination control strategy, isolator and barrier technology, aseptic process validation, and the regulatory change management that modernization programs require.

Modernization Program Experience

Our firm has extensive experience recruiting executives who have converted legacy aseptic operations to barrier technology while maintaining supply, with a clear understanding of sequencing, validation, and regulatory filing strategy.

Multi-Role Execution

Our team specializes in running coordinated operations, sterility assurance, engineering, regulatory, and technical searches in parallel, ensuring leaders are selected as a complementary unit aligned to a single modernization program.

Our Executive Search Strategy

Phase 1 — Modernization Program Alignment

Our consultants partnered directly with the Chief Executive Officer, Chief Quality Officer, and head of technical operations to review inspection feedback, facility conditions, conversion plans, product portfolio, and regulatory filing requirements, defining five executive profiles aligned with the modernization program.

Phase 2 — Talent Identification & Mapping

Our research team performed an extensive talent mapping initiative targeting sterile operations, sterility assurance, barrier engineering, regulatory CMC, and manufacturing science executives at sterile injectables manufacturers, pharmaceutical and biopharmaceutical companies, and sterile CDMOs who had led documented Annex 1 and isolator conversion programs. Over 410 executives were systematically assessed across these sectors.

Phase 3 — Candidate Engagement

Priority during outreach was given to leaders with a documented history of converting open-cleanroom lines to isolator and RABS technology, building Annex 1-compliant contamination control strategies, revalidating aseptic processes across multiple facilities, managing large regulatory variation programs across jurisdictions, and maintaining supply through modernization. Only candidates meeting these strict performance baselines advanced.

Phase 4 — Selection Process

Finalists presented modernization plans to the Chief Executive Officer and Chief Quality Officer, completed structured leadership assessments, and underwent reference verification focused on quantified compliance, conversion, and supply outcomes.

Key Outcomes

• 410+ sterile manufacturing, quality, and regulatory executive profiles mapped across North America.
• Successfully placed a synchronized leadership tier spanning sterile operations, sterility assurance, barrier engineering, regulatory CMC, and manufacturing science within seven months.
• Converted nine filling lines to isolator and RABS technology within thirty months.
• Secured approval of more than 400 regulatory variations with no supply gaps.
• Reduced aseptic interventions by 80% and maintained supply of all 90 products.
• Passed European and FDA inspections at all facilities with no critical observations.